Luis Felipe Leite, Teaching assistant at Meta-Analysis Academy, shared on LinkedIn:
“There is a mismatch between progression-free survival and overall survival results across randomized clinical trials of antibody-drug conjugates (ADCs) for breast cancer.
In our new paper, we systematically quantify this discordance and discuss its implications for interpreting clinical benefit.
Read the accepted manuscript ahead of print:
This work was brilliantly led by Luiz de Almeida and made possible by a remarkable collaborative effort. I am deeply grateful to our international team and mentors.”
Title: Treatment effect discrepancy between PFS and OS in antibody-drug conjugate trials for metastatic breast cancer: a meta-epidemiologic analysis
Authors: Luiz Felipe Costa de Almeida, Anelise Poluboiarinov Cappellaro, Mariana Macambira Noronha, Lucas Diniz da Conceição, Lorrany Larisse Costa Rodrigues, Luís Felipe Leite, Rodolfo Garza-Morales, Brenda Ernst, Andreia Cristina de Melo, Jessé Lopes da Silva, Paolo Tarantino, Dario Trapani, Felipe Batalini.
Read the full article.
This also can be interesting:
